
Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.
Blueprint Medicines, founded in Cambridge, US, is dedicated to developing targeted cancer treatments for genomically defined patients. The company's core mission is to improve patient outcomes by creating precision therapies that address the molecular underpinnings of cancer. Blueprint Medicines offers a range of products, including AYVAKIT®/AYVAKYT® (avapritinib), which targets specific genetic mutations in cancer cells. Their market focus is on providing innovative solutions for patients with rare and difficult-to-treat cancers.
Notable affiliated individuals include industry experts and seasoned professionals in biomedical research and oncology. The company has attracted significant investment from leading healthcare investors. Key achievements include presenting promising clinical data at major conferences such as EAACI, EHA, and ASCO, highlighting the sustained benefits of their therapies. Blueprint Medicines has made a substantial impact on the field of precision oncology, offering hope and improved treatment options for patients with genetically defined cancers.

BeOne Medicines
beigene.com

Foundation Medicine

Revolution Medicines
revmed.com

Clovis Oncology

Accelerated Pharma

Seagen
seagen.com

xCures
xcures.com

BridgeBio Pharma
bridgebio.com

Verastem

Kronos Bio

Exelixis
exelixis.com

G1 Therapeutics
g1therapeutics.com

Arvinas
arvinas.com

Novocure
novocure.com

Praxis Precision Medicines
Companies similar to Blueprint Medicines include BeOne Medicines, Foundation Medicine, Revolution Medicines and Clovis Oncology.
Blueprint Medicines was founded in 2008.
Blueprint Medicines' headquarters is located in Cambridge, MA, US.
Blueprint Medicines' most recent funding round was for $1.3B (USD) in June 2022.
As of Jun 30, 2022, Blueprint Medicines has raised a total of $2.4B (USD).
Blueprint Medicines has 641 employees as of Feb 6, 2024.